New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Study met its primary endpoint demonstrating safety and tolerability of CMTX-101 in people with cystic fibrosisCMTX-101 ...

About one in nine adults suffer from chronic insomnia and its residual effects like drowsiness, cognitive issues, and ...

The study presents data on the possible connection of respiratory pathologies like pneumonia in a cohort of dolphins with altered composition and concomitant perturbed biophysical properties of ...

Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...

Among 8- to 9-year-olds, those with vs. without maternal gestational diabetes mellitus exposure had two reduced measures of ...

Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

Early diagnosis of pulmonary arterial hypertension improves five-year survival by 42%, compared with delayed diagnosis, a ...

The gut bacteria B. adolescentis eased lung scarring in a pulmonary fibrosis mouse model, showing potential as a preventive ...

Researchers in China report that a simple heart ultrasound measure of left ventricular underfilling is a valuable prognostic ...